| Michelle Keizerweerd, CRNA | |
|
7365 Main St, Suite 310, Stratford, CT 06614-1300 | |
| (203) 384-3174 | |
| (203) 384-4619 |
| Full Name | Michelle Keizerweerd |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 14 Years |
| Location | 7365 Main St, Stratford, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558682237 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| White Plains Hospital Center | White plains, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Greenwich Anesthesiology Associates Pc | 2163315425 | 39 |
| North American Partners In Anesthesia Llp | 7719885771 | 503 |
News Archive
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
For Keith Jerome, M.D, Ph.D., the most intriguing question about cancer is not what causes it but why our bodies fail to defend us from the disease after it strikes.
To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus.
The increased risk of kidney injury related to the use of hydroxyethyl starch (HES) in resuscitation fluids reflects the mass of HES molecules, according to a report in Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
› Verified 2 days ago
| Entity Name | Yale University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205822236 PECOS PAC ID: 9436061736 Enrollment ID: O20031105000015 |
News Archive
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
For Keith Jerome, M.D, Ph.D., the most intriguing question about cancer is not what causes it but why our bodies fail to defend us from the disease after it strikes.
To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus.
The increased risk of kidney injury related to the use of hydroxyethyl starch (HES) in resuscitation fluids reflects the mass of HES molecules, according to a report in Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
› Verified 2 days ago
| Entity Name | Bridgeport Anesthesia Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174549257 PECOS PAC ID: 7113824616 Enrollment ID: O20031215000038 |
News Archive
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
For Keith Jerome, M.D, Ph.D., the most intriguing question about cancer is not what causes it but why our bodies fail to defend us from the disease after it strikes.
To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus.
The increased risk of kidney injury related to the use of hydroxyethyl starch (HES) in resuscitation fluids reflects the mass of HES molecules, according to a report in Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
› Verified 2 days ago
| Entity Name | Greenwich Anesthesiology Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972557486 PECOS PAC ID: 2163315425 Enrollment ID: O20040203000088 |
News Archive
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
For Keith Jerome, M.D, Ph.D., the most intriguing question about cancer is not what causes it but why our bodies fail to defend us from the disease after it strikes.
To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus.
The increased risk of kidney injury related to the use of hydroxyethyl starch (HES) in resuscitation fluids reflects the mass of HES molecules, according to a report in Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
› Verified 2 days ago
| Entity Name | Greater Connecticut Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730837576 PECOS PAC ID: 1254727167 Enrollment ID: O20220401000467 |
News Archive
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
For Keith Jerome, M.D, Ph.D., the most intriguing question about cancer is not what causes it but why our bodies fail to defend us from the disease after it strikes.
To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus.
The increased risk of kidney injury related to the use of hydroxyethyl starch (HES) in resuscitation fluids reflects the mass of HES molecules, according to a report in Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michelle Keizerweerd, CRNA 7365 Main St, Suite 310, Stratford, CT 06614-1300 Ph: (203) 384-3174 | Michelle Keizerweerd, CRNA 7365 Main St, Suite 310, Stratford, CT 06614-1300 Ph: (203) 384-3174 |
News Archive
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
For Keith Jerome, M.D, Ph.D., the most intriguing question about cancer is not what causes it but why our bodies fail to defend us from the disease after it strikes.
To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus.
The increased risk of kidney injury related to the use of hydroxyethyl starch (HES) in resuscitation fluids reflects the mass of HES molecules, according to a report in Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
› Verified 2 days ago
Meghan Leary, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7365 Main St, Suite 310, Stratford, CT 06614 Phone: 800-586-2153 | |
Ms. Carrie R Jordan, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7365 Main St Ste 310, Stratford, CT 06614 Phone: 203-384-3174 Fax: 203-384-4619 |